Clinical Research Trials
Retinal diseases are a leading cause of vision loss and blindness, affecting millions of people worldwide. Clinical trials are vital to the development of new treatments and therapies for these conditions, and there are many ongoing trials testing promising new approaches.
Star Retina is proud to take part in clinical research trials for many common retinal conditions. Below are trials for which we are currently enrolling new patients and those that have been completed.
ETA: CLOSEDSponsor: KODIAK GLOW A Prospective, Randomized, Double-masked, Active Comparatorcontrolled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
ETA: CLOSEDSponsor: ORA ANX007-GA-0 A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Geographic Atrophy (GA)
ETA: CLOSEDSponsor: KODIAK Daylight A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)
ETA: CLOSEDSponsor: OcuTerra-OTT 166-201 DREAM OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
ETA: CLOSEDSponsor: Opthea OPT-302-1005 COAST Eyelea OPT-302-1005-COAST A Phase 3, Multicentre, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
For referring doctors or patients who wish to learn more about our research protocols or activities, please continue reading below or contact our office at 817-378-4777